OpenAI CEO Sam Altman Says a Cure for Cancer Is Not Enough to Justify AI’s Risks, ‘We Should Set Our Sights Higher’

Sam Altman was recently asked on Bloomberg why the artificial intelligence (AI) industry has failed to convince ordinary people that any of this is good for them. He agreed that it has failed, said OpenAI is part of the problem, and then argued that the industry's most common answer to the question is not good enough, either.

"You hear some people talk about, 'Well, we're going to give you a cure for cancer, and that's so great. So we're going to take these risks and you're going to have to have less power and autonomy,'" he said. "We want people to have more power and autonomy. I don't think a cure for cancer is enough." 

He added immediately: "Wonderful thing to have, obviously, but we should set our sights higher."

The question that prompted this comment came out of a political argument rather than a technical one. The interviewer put to Altman that U.S. Treasury Secretary Scott Bessent said at G20 that the AI industry has done a “terrible job” of explaining how AI benefits ordinary Americans. Altman did not push back. "I think the industry has done a terrible job of this on the whole," he said. “I think we have done a bad job ourselves, maybe better than some others, worse than some others.”

Sponsored Content: StartEngine Private provides access to Pre-IPO companies. Explore Startup Investing Today. 

The cancer line has a specific target, even though Altman did not name one. Anthropic's Dario Amodei has made the case that AI will earn public trust by delivering something undeniable, curing disease being the standard example, and that framing has become the default defense of the industry's risk profile. Altman's position is that a cure for cancer would be a wonderful thing that still would not justify a trade in which people end up with less control over their own lives. Whether that is a higher bar or a rhetorical dodge depends on what he thinks the higher bar is. "We want these tools to enable a boom in creativity and entrepreneurship, in people figuring out new ways to be useful to each other," he said.

So there are three positions in one exchange, and they do not line up. A sitting Treasury Secretary says the industry cannot explain its own benefit. An AI chief executive says the way to prove the benefit is to cure something. And Sam Altman says curing something is not a high enough bar to clear. Two of those three are arguing about how to reassure the public. The third is arguing about what the public should be asking for.

The most striking thing Altman said was also the smallest. "I think people rightly get afraid when they feel like AI leaders might not quite want that [power and autonomy] for them," he said. The remark is a chief executive conceding that the public's suspicion of people in his position is rational, which is a different claim from conceding that the messaging has been poor.

It is also worth noting what Altman did not do in the interview. He did not promise a timeline, did not name a product, and did not offer a number. The interview was a defense of the industry's purpose rather than of its capabilities, which is a shift in itself; the case for AI has spent three years being made in benchmarks and is now being made in terms of autonomy and self-employment.

OpenAI is private, so there is nothing here for an investor to price. The context that matters is reputational, and Altman has spent the year under attack from both directions — by an administration official who says the industry cannot justify itself to the public, and by rivals who think it justifies itself badly. He has also feuded with Elon Musk over roughly the same question of who should be trusted to build AI. The 'AI leaders might not want that for you' line reads differently with that in the background.

What Altman is proposing, stripped of the framing, is that the industry stops asking to be judged on what it cures and starts asking to be judged on whether people end up with more power or less. It is a much harder standard to demonstrate than a cure, and unlike a cure, nobody has proposed how you would measure it. How AI could reshape work is the version of this argument the industry usually makes, and it is the one Altman is implicitly declining to make.

On the date of publication, Caleb Naysmith did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.